Best of Gastroenterology

In this article collection, we have selected recent, high-impact articles from the Karger gastroenterology journals to capture the latest groundbreaking research in the field. The articles cover a range of topics from gastrointestinal cancer, surgery, therapeutics, and clinical outcomes, to inflammatory bowel disease, gut microbiota, biomarkers, surgery, and more.

•  
  Management of Hepatocellular Carcinoma in Japan: JSH Consensus Statements and Recommendations 2021 Update
  Masatoshi Kudo; Yusuke Kawamura; Kiyoshi Hasegawa; Ryosuke Tateishi; Kazuya Kariyama; Shuichiro Shiina; Hidenori Toyoda; Yasuharu Imai; Atsushi Hiraoka; Masafumi Ikeda; Namiki Izumi; Michihisa Moriguchi; Sadahisa Ogasawara; Yasunori Minami; Kazuomi Ueshima; Takamichi Murakami; Shiro Miyayama; Osamu Nakashima; Hirohisa Yano; Michiie Sakamoto; Etsuro Hatano; Mitsuo Shimada; Norihiro Kokudo; Satoshi Mochida; Tetsuo Takehara; HCC Expert Panel of the Japan Society of Hepatology
  Liver Cancer (2021) 10 (3): 181–223 (DOI:10.1159/000514174)

   

•  
  Downstaging and Resection of Initially Unresectable Hepatocellular Carcinoma with Tyrosine Kinase Inhibitor and Anti-PD-1 Antibody Combinations
  Xiao-Dong Zhu; Cheng Huang; Ying-Hao Shen; Yuan Ji; Ning-Ling Ge; Xu-Dong Qu; Lingli Chen; Wen-Kai Shi; Mei-Ling Li; Jin-Jin Zhu; Chang-Jun Tan; Zhao-You Tang; Jian Zhou; Jia Fan; Hui-Chuan Sun
  Liver Cancer (2021) 10 (4): 320–329 (DOI:10.1159/000514313)

   

•  
  MRI Features for Predicting Microvascular Invasion of Hepatocellular Carcinoma: A Systematic Review and Meta-Analysis
  Seung Baek Hong; Sang Hyun Choi; So Yeon Kim; Ju Hyun Shim; Seung Soo Lee; Jae Ho Byun; Seong Ho Park; Kyung Won Kim; Suk Kim; Nam Kyung Lee
  Liver Cancer (2021) 10 (2): 94–106 (DOI:10.1159/000513704)

   

•  
  Clinical Outcomes with Multikinase Inhibitors after Progression on First-Line Atezolizumab plus Bevacizumab in Patients with Advanced Hepatocellular Carcinoma: A Multinational Multicenter Retrospective Study
  Changhoon Yoo; Jwa Hoon Kim; Min-Hee Ryu; Sook Ryun Park; Danbi Lee; Kang Mo Kim; Ju Hyun Shim; Young-Suk Lim; Han Chu Lee; Joycelyn Lee; David Tai; Stephen Lam Chan; Baek-Yeol Ryoo
  Liver Cancer (2021) 10 (2): 107–114 (DOI:10.1159/000512781)

   

•  
  Clinical-Radiomic Analysis for Pretreatment Prediction of Objective Response to First Transarterial Chemoembolization in Hepatocellular Carcinoma
  Mingyu Chen; Jiasheng Cao; Jiahao Hu; Win Topatana; Shijie Li; Sarun Juengpanich; Jian Lin; Chenhao Tong; Jiliang Shen; Bin Zhang; Jennifer Wu; Christine Pocha; Masatoshi Kudo; Amedeo Amedei; Franco Trevisani; Pil Soo Sung; Victor M. Zaydfudim; Tatsuo Kanda; Xiujun Cai; AME Hepatocellular Carcinoma Collaborative Group
  Liver Cancer (2021) 10 (1): 38–51 (DOI:10.1159/000512028)

   

•  
  Proactive versus Reactive Therapeutic Drug Monitoring: Why, When, and How?
  Manar Shmais; Miguel Regueiro; Jana G. Hashash
  Inflamm Intest Dis (2022) 7 (1): 50–58 (DOI:10.1159/000518755)

   

•  
  Surgical Resection for Crohn’s and Cancer: A Comparison of Disease-Specific Risk Factors and Outcomes
  David W. Larson; Mohamed A. Abd El Aziz; William Perry; Kevin T. Behm; Sherief Shawki; Jay Mandrekar; Kellie L. Mathis; Fabian Grass
  Dig Surg (2021) 38 (2): 120–127 (DOI:10.1159/000511909)

   

•  
  Worldwide Practice in Gastric Cancer Surgery: A 6-Year Update
  Emma C. Gertsen; Hylke J.F. Brenkman; Leonie Haverkamp; Matthew Read; Jelle P. Ruurda; Richard van Hillegersberg
  Dig Surg (2021) 38 (4): 266–274 (DOI:10.1159/000515768)

   

•  
  NASH/Liver Fibrosis Prevalence and Incidence of Nonliver Comorbidities among People with NAFLD and Incidence of NAFLD by Metabolic Comorbidities: Lessons from South Korea
  Jiyoon Park; Eunice Yewon Lee; Jie Li; Mi Jung Jun; Eileen Yoon; Sang Bong Ahn; Chuanli Liu; Hongli Yang; Fajuan Rui; Biyao Zou; Linda Henry; Dong Hyun Lee; Dae Won Jun; Ramsey C. Cheung; Mindie H. Nguyen
  Dig Dis (2021) 39 (6): 634–645 (DOI:10.1159/000514953)

   

•  
  The Fear of Gastric Cancer in Patients with Dyspepsia: Challenge in Specialist Care Gastroenterology
  Lukas Macke; Christian Schulz; Peter Malfertheiner
  Dig Dis (2022) 40 (4): 409–416 (DOI:10.1159/000518394)

   

•  
  Biomarkers of Inflammation in Inflammatory Bowel Disease: How Long before Abandoning Single-Marker Approaches?
  Gabriele Dragoni; Tommaso Innocenti; Andrea Galli
  Dig Dis (2021) 39 (3): 190–203 (DOI:10.1159/000511641)

   

•  
  Epidemiological Trends and Future Perspectives of Gastric Cancer in Eastern Asia
  Masau Sekiguchi; Ichiro Oda; Takahisa Matsuda; Yutaka Saito
  Digestion (2022) 103 (1): 22–28 (DOI:10.1159/000518483)

   

•  
  The Ideal Helicobacter pylori Treatment for the Present and the Future
  Sho Suzuki; Chika Kusano; Toshiki Horii; Ryoji Ichijima; Hisatomo Ikehara
  Digestion (2022) 103 (1): 62–68 (DOI:10.1159/000519413)

   

•  
  Gut Microbiota Dysbiosis Drives the Development of Colorectal Cancer
  Xiaoyan Fan; Yuelei Jin; Guang Chen; Xueqiang Ma; Lixia Zhang
  Gastroenterologia (1964) 102 (4): 508–515 (DOI:10.1159/000508328)

   

•  
  Acute Gastric Dilatation: A Cause for Concern
  Danial Haris Shaikh; Abhilasha Jyala; Shehriyar Mehershahi; Chandni Sinha; Sridhar Chilimuri
  Case Rep Gastroenterol (2021) 15 (1): 171–177 (DOI:10.1159/000512401)